Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.04, $0.54 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $303.5 million versus the consensus estimate of $320 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.